閱文集團(00772.HK)與傳音控股合作拓非洲在線閱讀市場
閱文集團(00772.HK)宣布,與傳音控股達成戰略合作,共同開拓及發展非洲在線閱讀市場。目前傳音控股正在申請科創板上市。
根據招股書,傳音控股主要從事以手機為核心的智能終端的設計、研發、生產、銷售和品牌運營,主要產品為TECNO、itel 和Infinix三大品牌手機。
合作約定,雙方將結合閱文豐富的原創內容庫和在線閱讀平台運營經驗以及傳音在非洲市場廣闊的分發渠道,向當地用戶提供優質的在線閱讀內容和產品。非洲平台將首先推出閱文現有的近三萬部英文作品,並將陸續上線其他當地語言版本以及本地原創的內容。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.